Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06445959 · ClinicalTrials.gov registry record · Phase 1
Phase 1b/2 Study of Decitabine and Venetoclax in Combination With the Targeted Mutant IDH1 Inhibitor Olutasidenib
A Phase 1 study of Mutant IDH1 Inhibitor Olutasidenib, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 78
- Enrollment target
- 1
- Study location
NCT06445959 is a Phase 1 study of Mutant IDH1 Inhibitor Olutasidenib that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 78 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06445959, a Phase 1 study of Mutant IDH1 Inhibitor Olutasidenib, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 78 participants
- Enrollment target
- 1
- Study location
Study Summary
To find a recommended combination dose of decitabine and venetoclax that can be given in combination with olutasidenib to participants with AML.
Conditions Studied
Interventions
- DRUG Venetoclax
- DRUG Decitabine
- DRUG Olutasidenib
- DRUG Decitabine/cedazuridine
Study Locations (1)
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 78 participants |
| Start Date | 2024-08-29 |
| Est. Completion | 2029-06-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06445959
The ClinicalTrials.gov registry entry for NCT06445959 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 78 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Mutant IDH1 Inhibitor Olutasidenib appearing as the primary indexed condition, and to 4 interventions - of which Venetoclax is the first listed.
NCT06445959 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT06445959 about?
NCT06445959 is a clinical study titled "Phase 1b/2 Study of Decitabine and Venetoclax in Combination With the Targeted Mutant IDH1 Inhibitor Olutasidenib". To find a recommended combination dose of decitabine and venetoclax that can be given in combination with olutasidenib to participants with AML.
What is the current status of trial NCT06445959?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 78 participants. The study started on 2024-08-29. Estimated completion is 2029-06-30.
What conditions does trial NCT06445959 study?
This clinical trial studies the following conditions: Mutant IDH1 Inhibitor Olutasidenib.
What interventions are being tested in trial NCT06445959?
The interventions under investigation include: Venetoclax (DRUG), Decitabine (DRUG), Olutasidenib (DRUG), Decitabine/cedazuridine (DRUG).
Who is sponsoring clinical trial NCT06445959?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06445959 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.